Evidence map›Paper›PMID 39532372›Full record

SynthesisBMJ open2024

Prognostic role of systemic inflammation response index in patients with non-small cell lung cancer: a meta-analysis.

Xingchen Ye, Menglu Dai, Zhuofang Xiang

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Association between the systemic inflammation response index and prognosis in lung cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. The Systemic Inflammation Response Index (SIRI) for Stratifying Mortality Risk in Multidrug-Resistant Lower Respiratory Tract Infections Acquired in Hospital Settings.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xingchen YeClinical Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.
Menglu DaiClinical Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.
Zhuofang XiangClinical Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China xiangzhuofang@163.com.ORCID http://orcid.org/0009-0000-9041-8862

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe significance of the systemic inflammation response index (SIRI) for predicting prognostic outcomes in patients with non-small cell lung cancer (NSCLC) has been analysed in previous studies, but no consistent conclusions have been obtained. Consequently, the present meta-analysis was performed to identify the significance of SIRI in predicting the prognosis of NSCLC.

designThis study followed the PRISMA guidelines. DATA SOURCES: PubMed, Web of Science and Embase databases were searched between their inception and 26 November 2023. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Studies investigating the relationship between SIRI and survival outcomes of patients with NSCLC were included. DATA EXTRACTION AND SYNTHESIS: The value of SIRI in predicting prognosis in NSCLC cases was predicted using combined hazard ratios (HRs) and 95% CIs.

resultsNine articles with 3728 cases were enrolled in this study. Based on our combined data, a higher SIRI value was markedly linked with poor overall survival (OS) (HR=2.08, 95% CI 1.68 to 2.58, p<0.001) and inferior progression-free survival (PFS) (HR=1.74, 95% CI 1.47 to 2.07, p<0.001) of NSCLC. According to the subgroup analysis, country, history and cut-off value did not affect the significance of SIRI in predicting OS and PFS in NSCLC (p<0.05).

conclusionsA higher SIRI value was significantly associated with both OS and PFS in patients with NSCLC. Moreover, SIRI had a stable prognostic efficiency for NSCLC in various subgroups.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansInflammationPrognosisAdult oncologyImmunityImmunologyMeta-analysisThoracic medicine

Identifiers

PMID39532372
PMCPMC11575272

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.